Journal of healthcare quality research · 2025
A retrospective cohort study of onco-hematologic inpatients with SACT at the end of life in a single cancer institution: Differences between solid tumors and hematological neoplasms.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pétriz L, Vidal A, Germà J R, Loureiro E, Muniesa J, Ferro T
Аннотация
BACKGROUND: This study compares mortality indicators in patients with solid tumors (ST) and hematological neoplasms (HN) who died in the hospital during systemic anticancer therapy (SACT) in the last 30 days of life. We used indicators described by Earle: SACT<30d, SACT<14d, therapeutic regimen changes, and palliative care referrals. We also analyzed the impact of palliative care availability on patient survival.
METHODS: Between 2017 and 2022, we identified, validated, and registered 2285 cases through our institution's Mortality Subcommittee (MS) that met the inclusion criteria for this cohort.
RESULTS: We observed differences in indicators between ST and HN consistent with published literature. These differences occurred both in therapeutic intensity (higher in HN) and in palliative care referrals (higher percentage for ST). When analyzing survival from advanced disease definition to death, no statistically significant differences emerged between patients with HN versus ST, or between those with and without palliative care.
CONCLUSIONS: The published differences between subgroups (ST vs HN) persist even in our hospital death cohort, confirming the need for pathology-specific standards.
METHODS: Between 2017 and 2022, we identified, validated, and registered 2285 cases through our institution's Mortality Subcommittee (MS) that met the inclusion criteria for this cohort.
RESULTS: We observed differences in indicators between ST and HN consistent with published literature. These differences occurred both in therapeutic intensity (higher in HN) and in palliative care referrals (higher percentage for ST). When analyzing survival from advanced disease definition to death, no statistically significant differences emerged between patients with HN versus ST, or between those with and without palliative care.
CONCLUSIONS: The published differences between subgroups (ST vs HN) persist even in our hospital death cohort, confirming the need for pathology-specific standards.